Since the United States Food and Drug Administration approved exenatide in 2005, it took decades for the American Society of Anesthesiologists (ASA) to identify and address perioperative safety concerns, if any, among patients using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as exenatide. This delay could be due to several factors: GLP-1 RAs were initially
To anesthetize, or not to anesthetize: a pervasive dilemma of the GLP-1 era originally appeared in KevinMD.com.
